Comparison of the Clinical Efficacy of Gemcitabine and Pirarubicin in the Treatment of Bladder Cancer after Electroresection

Abstract

Objective: This paper aims to compare the effects of gemcitabine and pirarubicin in treating bladder cancer after electroresection. Methods: Bladder cancer patients who underwent bladder cancer resection in our hospital from January 2018 to January 2022 were selected as research subjects. According to the computer grouping method, 60 patients were divided into Group A (pirarubicin) and Group B (gemcitabine), and the therapeutic effects of the two groups of patients were compared. Results: The statistical significance of the tumor markers and related factor levels of patients in Group A and Group B before treatment was not established (P > 0.05). The levels of tumor markers and related factors of patients in Group B after treatment were lower than those of Group A (P < 0.05). There was no difference in the quality of life scores of patients in Group A and Group B before treatment (P > 0.05). After treatment, the quality of life scores of patients in Group B was higher than those in Group A (P < 0.05). The incidence rates of dysuria, hematuria, cystitis, and rash in Group B patients were less than those in group A (P < 0.05). The recurrence rate of patients in Group B was higher than in group A (P < 0.05). Conclusion: Both gemcitabine and pirarubicin are commonly used chemotherapy drugs after electroresection for bladder cancer. Compared with pirarubicin, gemcitabine is more effective and can improve the quality of life of bladder cancer patients.